LAG3, lymphocyte activating 3, 3902

N. diseases: 154; N. variants: 3
Disease: Tumor Immunity ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C1519680
Disease: Tumor Immunity
Tumor Immunity 		0.030 Biomarker phenotype BEFREE These results provide the framework for clinical application of heteroclitic BCMA<sub>72-80</sub> peptide, alone and in combination with anti-LAG3 and/or anti-OX40 therapy, in vaccination and/or adoptive immunotherapeutic strategies to generate long-lasting anti-tumor immunity in patients with MM or other BCMA expressing tumors. 30872779 2019
CUI: C1519680
Disease: Tumor Immunity
Tumor Immunity 		0.030 Biomarker phenotype BEFREE Lymphocyte-activation gene-3 (LAG-3) is another important immune checkpoint, which can inhibit tumor immunity. 30147330 2018
CUI: C1519680
Disease: Tumor Immunity
Tumor Immunity 		0.030 Biomarker phenotype BEFREE Taken together, these data suggest that LAG3-expressing CD4<sup>+</sup>CD25<sup>-</sup> T cells represent another regulatory immune cell type with potential to interfere with anti-tumor immunity. 28935468 2017